Engineering a novel, stable dimeric streptavidin with lower isoelectric point.

Area of Science:

• Biochemistry
• Protein Engineering
• Structural Biology

Background:

• Streptavidin's tetrameric structure limits its use in some biomedical applications.
• Engineering streptavidin variants with altered quaternary structures is desirable for improved pharmacokinetics.

Purpose of the Study:

• To rationally engineer a soluble, stable two-chain dimeric streptavidin (TCD) from wild-type streptavidin.
• To investigate mutations that disrupt the tetramer and stabilize a dimer interface.

Main Methods:

• Utilized 3D structural examination and binding free-energy calculations to guide mutation selection.
• Introduced specific amino acid substitutions (e.g., W120D, L124N, V125S, H127D) at subunit interfaces.
• Purified engineered streptavidin variants using gel-filtration chromatography.

Main Results:

• Successfully engineered three TCD variants (TCD-1, TCD-2, TCD-3).
• TCD-2 demonstrated the best performance: a stable, active dimer with a biotin dissociation constant (Kd) of ~1x10(-7) M.
• Mutations, including H127D for electrostatic repulsion and hydrophilic substitutions at W120, L124, V125, enhanced dimer stability and solubility.

Conclusions:

• Rational engineering of low-isoelectric point (pI) dimeric streptavidins is feasible.
• Engineered dimeric streptavidin mutants with net negative charges may offer advantages in radioimmunotherapy due to faster blood and kidney clearance compared to antibodies or wild-type streptavidin.